Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (60479)	3/10/1999 2:36:00 AM
From: blackmerlin	Read Replies (2) \| Respond to of 119973

CYPH moving up, fundamentals look good: CYPH (Cytoclonal Pharmaceuticals Inc.) moving up yesterday, +3/8 (+5.36%) to 7 3/8. Fundamentals look good. biz.yahoo.com -Indicates company received payment from Bristol Myers Squibb for fungal fermentation of Taxol (a cheaper way to make a $1 billion anticancer drug, and Taxol sales are increasing partially due to new uses in combination therapy - i.e. with Genentech's Herceptin). -Cytoclonal has integrated approach in the Taxol area - Fungal Taxol production plus the elucidation of Taxol biosynthetic pathways. biz.yahoo.com -Shows CYPH has rational drug platform in place for the discovery of new therapeutic compounds (could open up new licensing opportunities if successful). IMO, I like CYPH, may have potential to hit 10 1/8 in the short term. Regards, Jake Blackmerlin